The multifaceted proprotein convertases: Their unique, redundant, complementary, and opposite functions

Journal of Biological Chemistry

Volumn 288, Issue 30, 2013, Pages 21473-21481

  Seidah, Nabil G ^a   Sadr, Mohamad S ^a,b   Chrétien, Michel ^a,b   Mbikay, Majambu ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; CONVERTASES; IN-PHASE; IN-VIVO; LDL CHOLESTEROL; LYSOSOMAL DEGRADATION; THERAPEUTIC TARGETS;

BIOCHEMISTRY; BIOLOGY;

MICROCOMPUTERS;

CHOLESTEROL; FURIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PCSK9; PEGDINETANIB; PROPROTEIN CONVERTASE 1; PROPROTEIN CONVERTASE 2; PROPROTEIN CONVERTASE 4; PROPROTEIN CONVERTASE 5; PROPROTEIN CONVERTASE 7; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; PROTEIN PACE4; PROTEIN SKI 1; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ADULTHOOD; AMINO ACID SEQUENCE; AUTOSOMAL DOMINANT DISORDER; DEVELOPMENT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME SUBSTRATE; GENE MUTATION; GOLGI COMPLEX; HUMAN; HYPERCHOLESTEROLEMIA; LYSOSOME; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; RNA INTERFERENCE; SINGLE DRUG DOSE;

CARDIOVASCULAR DISEASE; CELL SURFACE RECEPTOR; CHOLESTEROL METABOLISM; FURIN-LIKE PROTEASE; INTRACELLULAR PROCESSING; LOW DENSITY LIPOPROTEIN (LDL); PRECURSOR PROCESSING; PROPROTEIN CONVERTASE; PROTEASE; SECRETORY PROTEINS;

ANIMALS; CHOLESTEROL; HUMANS; MICE; MICE, KNOCKOUT; MULTIGENE FAMILY; PROPROTEIN CONVERTASES; RECEPTORS, LDL; SUBSTRATE SPECIFICITY; SUBTILISINS;

EID: 84881238159     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.R113.481549     Document Type: Review

References (100)

1. Chretien, M. (2011) The prohormone theory and the proprotein convertases: it is all about serendipity. Methods Mol. Biol. 768, 13-19
2. Steiner, D. F. (2011) On the discovery of precursor processing. Methods Mol. Biol. 768, 3-11
3. Seidah, N. G., and Prat, A. (2012) The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 11, 367-383
4. Marcinkiewicz, M., Day, R., Seidah, N. G., and Chrétien, M. (1993) Ontogeny of the prohormone convertases PC1 and PC2 in the mouse hypophysis and their colocalization with corticotropin and-melanotropin. Proc. Natl. Acad. Sci. U.S.A. 90, 4922-4926
5. Steiner, D. F. (1998) The proprotein convertases. Curr. Opin. Chem. Biol. 2, 31-39
6. Seidah, N. G., Mayer, G., Zaid, A., Rousselet, E., Nassoury, N., Poirier, S., Essalmani, R., and Prat, A. (2008) The activation and physiological functions of the proprotein convertases. Int. J. Biochem. Cell Biol. 40, 1111-1125
7. Zhu, X., Zhou, A., Dey, A., Norrbom, C., Carroll, R., Zhang, C., Laurent, V., Lindberg, I., Ugleholdt, R., Holst, J. J., and Steiner, D. F. (2002) Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc. Natl. Acad. Sci. U.S.A. 99, 10293-10298
8. Furuta, M., Yano, H., Zhou, A., Rouillé, Y., Holst, J. J., Carroll, R., Ravazzola, M., Orci, L., Furuta, H., and Steiner, D. F. (1997) Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc. Natl. Acad. Sci. U.S.A. 94, 6646-6651
9. Roebroek, A. J., Umans, L., Pauli, I. G., Robertson, E. J., van Leuven, F., Van de Ven, W. J., and Constam, D. B. (1998) Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase furin. Development 125, 4863-4876
10. Essalmani, R., Zaid, A., Marcinkiewicz, J., Chamberland, A., Pasquato, A., Seidah, N. G., and Prat, A. (2008) In vivo functions of the proprotein convertase PC5/6 during mouse development: Gdf11 is a likely substrate. Proc. Natl. Acad. Sci. U.S.A. 105, 5750-5755
11. Constam, D. B., and Robertson, E. J. (2000) SPC4/PACE4 regulates a TGFβ signaling network during axis formation. Genes Dev. 14, 1146-1155
12. Seidah, N. G., Hamelin, J., Mamarbachi, M., Dong, W., Tardos, H., Mbikay, M., Chretien, M., and Day, R. (1996) cDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexin-like proteinases. Proc. Natl. Acad. Sci. U.S.A. 93, 3388-3393
13. Besnard, J., Ruda, G. F., Setola, V., Abecassis, K., Rodriguiz, R. M., Huang, X. P., Norval, S., Sassano, M. F., Shin, A. I., Webster, L. A., Simeons, F. R., Stojanovski, L., Prat, A., Seidah, N. G., Constam, D. B., Bickerton, G. R., Read, K. D., Wetsel, W. C., Gilbert, I. H., Roth, B. L., and Hopkins, A. L. (2012) Automated design of ligands to polypharmacological profiles. Nature 492, 215-220
14. Guillemot, J., Canuel, M., Essalmani, R., Prat, A., and Seidah, N. G. (2013) Implication of the proprotein convertases in iron homeostasis: PC7 sheds human transferrin receptor 1 and furin activates hepcidin. Hepatology 57, 2514-2524
15. Seidah, N. G., Mowla, S. J., Hamelin, J., Mamarbachi, A. M., Benjannet, S., Touré, B. B., Basak, A., Munzer, J. S., Marcinkiewicz, J., Zhong, M., Barale, J. C., Lazure, C., Murphy, R. A., Chrétien, M., and Marcinkiewicz, M. (1999) Mammalian subtilisin/kexin isozyme SKI-1: a widely expressed proprotein convertase with a unique cleavage specificity and cellular localization. Proc. Natl. Acad. Sci. U.S.A. 96, 1321-1326
16. Cheng, D., Espenshade, P. J., Slaughter, C. A., Jaen, J. C., Brown, M. S., and Goldstein, J. L. (1999) Secreted site-1 protease cleaves peptides corresponding to luminal loop of sterol regulatory element-binding proteins. J. Biol. Chem. 274, 22805-22812
17. Ye, J., Rawson, R. B., Komuro, R., Chen, X., Davé, U. P., Prywes, R., Brown, M. S., and Goldstein, J. L. (2000) ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol. Cell 6, 1355-1364
18. Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., and Chretien, M. (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U.S.A. 100, 928-933
19. Rashid, S., Curtis, D. E., Garuti, R., Anderson, N. N., Bashmakov, Y., Ho, Y. K., Hammer, R. E., Moon, Y. A., and Horton, J. D. (2005) Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. U.S.A. 102, 5374-5379
20. Zaid, A., Roubtsova, A., Essalmani, R., Marcinkiewicz, J., Chamberland, A., Hamelin, J., Tremblay, M., Jacques, H., Jin, W., Davignon, J., Seidah, N. G., and Prat, A. (2008) Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 48, 646-654
21. Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L., Grishin, N. V., Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2006) Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79, 514-523
22. Abifadel, M., Varret, M., Rabès, J. P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J. M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., and Boileau, C. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156
23. Timms, K. M., Wagner, S., Samuels, M. E., Forbey, K., Goldfine, H., Jammulapati, S., Skolnick, M. H., Hopkins, P. N., Hunt, S. C., and Shattuck, D. M. (2004) A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum. Genet. 114, 349-353
24. Zhou, A., Webb, G., Zhu, X., and Steiner, D. F. (1999) Proteolytic processing in the secretory pathway. J. Biol. Chem. 274, 20745-20748
25. Creemers, J. W., and Khatib, A. M. (2008) Knock-out mouse models of proprotein convertases: unique functions or redundancy? Front. Biosci. 13, 4960-4971
26. Seidah, N. G. (2011) The proprotein convertases, 20 years later. Methods Mol. Biol. 768, 23-57
27. Benjannet, S., Rondeau, N., Paquet, L., Boudreault, A., Lazure, C., Chrétien, M., and Seidah, N. G. (1993) Comparative biosynthesis, covalent post-translational modifications and efficiency of prosegment cleavage of the prohormone convertases PC1 and PC2: glycosylation, sulphation and identification of the intracellular site of prosegment cleavage of PC1 and PC2. Biochem. J. 294, 735-743
28. Qian, Y., Devi, L. A., Mzhavia, N., Munzer, S., Seidah, N. G., and Fricker, L. D. (2000) The C-terminal region of proSAAS is a potent inhibitor of prohormone convertase 1. J. Biol. Chem. 275, 23596-23601
29. Martens, G. J., Braks, J. A., Eib, D. W., Zhou, Y., and Lindberg, I. (1994) The neuroendocrine polypeptide 7B2 is an endogenous inhibitor of prohormone convertase PC2. Proc. Natl. Acad. Sci. U.S.A. 91, 5784-5787a
30. Bailyes, E. M., Shennan, K. I., Seal, A. J., Smeekens, S. P., Steiner, D. F., Hutton, J. C., and Docherty, K. (1992) A member of the eukaryotic subtilisin family (PC3) has the enzymic properties of the type 1 proinsulinconverting endopeptidase. Biochem. J. 285, 391-394
31. Bennett, D. L., Bailyes, E. M., Nielsen, E., Guest, P. C., Rutherford, N. G., Arden, S. D., and Hutton, J. C. (1992) Identification of the type 2 proinsulin processing endopeptidase as PC2, a member of the eukaryote subtilisin family. J. Biol. Chem. 267, 15229-15236
32. Furuta, M., Carroll, R., Martin, S., Swift, H. H., Ravazzola, M., Orci, L., and Steiner, D. F. (1998) Incomplete processing of proinsulin to insulin accompanied by elevation of des-31,32 proinsulin intermediates in islets of mice lacking active PC2. J. Biol. Chem. 273, 3431-3437
33. Zhu, X., Orci, L., Carroll, R., Norrbom, C., Ravazzola, M., and Steiner, D. F. (2002) Severe block in processing of proinsulin to insulin accompanied by elevation of des-64,65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3. Proc. Natl. Acad. Sci. U.S.A. 99, 10299-10304
34. Benjannet, S., Rondeau, N., Day, R., Chrétien, M., and Seidah, N. G. (1991) PC1 and PC2 are proprotein convertases capable of cleaving proopiomelanocortin at distinct pairs of basic residues. Proc. Natl. Acad. Sci. U.S.A. 88, 3564-3568
35. Dhanvantari, S., Seidah, N. G., and Brubaker, P. L. (1996) Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol. Endocrinol. 10, 342-355
36. Furuta, M., Zhou, A., Webb, G., Carroll, R., Ravazzola, M., Orci, L., and Steiner, D. F. (2001) Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice. J. Biol. Chem. 276, 27197-27202
37. Mbikay, M., Croissandeau, G., Sirois, F., Anini, Y., Mayne, J., Seidah, N. G., and Chrétien, M. (2007) A targeted deletion/insertion in the mouse Pcsk1 locus is associated with homozygous embryo preimplantation lethality, mutant allele preferential transmission and heterozygous female susceptibility to dietary fat. Dev. Biol. 306, 584-598
38. Anini, Y., Mayne, J., Gagnon, J., Sherbafi, J., Chen, A., Kaefer, N., Chrétien, M., and Mbikay, M. (2010) Genetic deficiency for proprotein convertase subtilisin/kexin type 2 in mice is associated with decreased adiposity and protection from dietary fat-induced body weight gain. Int. J. Obes. 34, 1599-1607
39. Wardman, J. H., Zhang, X., Gagnon, S., Castro, L. M., Zhu, X., Steiner, D. F., Day, R., and Fricker, L. D. (2010) Analysis of peptides in prohormone convertase 1/3 null mouse brain using quantitative peptidomics. J. Neurochem. 114, 215-225
40. Zhang, X., Pan, H., Peng, B., Steiner, D. F., Pintar, J. E., and Fricker, L. D. (2010) Neuropeptidomic analysis establishes a major role for prohormone convertase-2 in neuropeptide biosynthesis. J. Neurochem. 112, 1168-1179
41. Peinado, J. R., Laurent, V., Lee, S. N., Peng, B. W., Pintar, J. E., Steiner, D. F., and Lindberg, I. (2005) Strain-dependent influences on the hypothalamo-pituitary-adrenal axis profoundly affect the 7B2 and PC2 null phenotypes. Endocrinology 146, 3438-3444
42. Wei, S., Feng, Y., Che, F. Y., Pan, H., Mzhavia, N., Devi, L. A., McKinzie, A. A., Levin, N., Richards, W. G., and Fricker, L. D. (2004) Obesity and diabetes in transgenic mice expressing proSAAS. J. Endocrinol. 180, 357-368
43. Westphal, C. H., Muller, L., Zhou, A., Zhu, X., Bonner-Weir, S., Schambelan, M., Steiner, D. F., Lindberg, I., and Leder, P. (1999) The neuroendocrine protein 7B2 is required for peptide hormone processing in vivo and provides a novel mechanism for pituitary Cushing's disease. Cell 96, 689-700
44. Kincaid, A. E. (2001) Spontaneous circling behavior and dopamine neuron loss in a genetically hypothyroid mouse. Neuroscience 105, 891-898
45. Marcinkiewicz, M., Touraine, P., and Chrétien, M. (1994) Pan-neuronal mRNA expression of the secretory polypeptide 7B2. Neurosci. Lett. 177, 91-94
46. Helwig, M., Hoshino, A., Berridge, C., Lee, S. N., Lorenzen, N., Otzen, D. E., Eriksen, J. L., and Lindberg, I. (2013) The neuroendocrine protein 7B2 suppresses the aggregation of neurodegenerative disease-related proteins. J. Biol. Chem. 288, 1114-1124
47. Creemers, J. W., Choquet, H., Stijnen, P., Vatin, V., Pigeyre, M., Beckers, S., Meulemans, S., Than, M. E., Yengo, L., Tauber, M., Balkau, B., Elliott, P., Jarvelin, M. R., Van Hul, W., Van Gaal, L., Horber, F., Pattou, F., Froguel, P., and Meyre, D. (2012) Heterozygous mutations causing partial prohormone convertase 1 deficiency contribute to human obesity. Diabetes 61, 383-390
48. Thomas, G. (2002) Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol. 3, 753-766
49. Susan-Resiga, D., Essalmani, R., Hamelin, J., Asselin, M.-C., Benjannet, S., Chamberland, A., Day, R., Szumska, D., Constam, D., Bhattacharya, S., Prat, A., and Seidah, N. G. (2011) Furin is the major processing enzyme of the cardiac-specific growth factor bone morphogenetic protein 10. J. Biol. Chem. 286, 22785-22794
50. Roebroek, A. J., Taylor, N. A., Louagie, E., Pauli, I., Smeijers, L., Snellinx, A., Lauwers, A., Van de Ven, W. J., Hartmann, D., and Creemers, J. W. (2004) Limited redundancy of the proprotein convertase furin in mouse liver. J. Biol. Chem. 279, 53442-53450
51. Mesnard, D., Donnison, M., Fuerer, C., Pfeffer, P. L., and Constam, D. B. (2011) The microenvironment patterns the pluripotent mouse epiblast through paracrine furin and Pace4 proteolytic activities. Genes Dev. 25, 1871-1880
52. Malfait, A. M., Arner, E. C., Song, R. H., Alston, J. T., Markosyan, S., Staten, N., Yang, Z., Griggs, D. W., and Tortorella, M. D. (2008) Proprotein convertase activation of aggrecanases in cartilage in situ. Arch. Biochem. Biophys. 478, 43-51
53. Lei, X., Shi, F., Basu, D., Huq, A., Routhier, S., Day, R., and Jin, W. (2011) Proteolytic processing of angiopoietin-like protein 4 by proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity. J. Biol. Chem. 286, 15747-15756
54. Tassew, N. G., Charish, J., Seidah, N. G., and Monnier, P. P. (2012) SKI-1 and furin generate multiple RGMa fragments that regulate axonal growth. Dev. Cell 22, 391-402
55. Vincent, M. J., Sanchez, A. J., Erickson, B. R., Basak, A., Chretien, M., Seidah, N. G., and Nichol, S. T. (2003) Crimean-Congo hemorrhagic fever virus glycoprotein proteolytic processing by subtilase SKI-1. J. Virol. 77, 8640-8649
56. Sanchez, A. J., Vincent, M. J., Erickson, B. R., and Nichol, S. T. (2006) Crimean-Congo hemorrhagic fever virus glycoprotein precursor is cleaved by furin-like and SKI-1 proteases to generate a novel 38-kilodalton glycoprotein. J. Virol. 80, 514-525
57. Jin, W., Fuki, I. V., Seidah, N. G., Benjannet, S., Glick, J. M., and Rader, D. J. (2005) Proprotein convertases are responsible for proteolysis and inactivation of endothelial lipase. J. Biol. Chem. 280, 36551-36559
58. Garten, W., Hallenberger, S., Ortmann, D., Schäfer, W., Vey, M., Angliker, H., Shaw, E., and Klenk, H. D. (1994) Processing of viral glycoproteins by the subtilisin-like endoprotease furin and its inhibition by specific peptidylchloroalkylketones. Biochimie 76, 217-225
59. Xiao, Y., Chen, G., Richard, J., Rougeau, N., Li, H., Seidah, N. G., and Cohen, E. A. (2008) Cell-surface processing of extracellular human immunodeficiency virus type 1 Vpr by proprotein convertases. Virology 372, 384-397
60. Essalmani, R., Susan-Resiga, D., Chamberland, A., Abifadel, M., Creemers, J. W., Boileau, C., Seidah, N. G., and Prat, A. (2011) In vivo evidence that furin from hepatocytes inactivates PCSK9. J. Biol. Chem. 286, 4257-4263
61. Maret, D., Gruzglin, E., Sadr, M. S., Siu, V., Shan, W., Koch, A. W., Seidah, N. G., Del Maestro, R. F., and Colman, D. R. (2010) Surface expression of precursor N-cadherin promotes tumor cell invasion. Neoplasia 12, 1066-1080
62. Maret, D., Sadr, M. S., Sadr, E. S., Colman, D. R., Del Maestro, R. F., and Seidah, N. G. (2012) Opposite roles of furin and PC5A in N-cadherin processing. Neoplasia 14, 880-892
63. Koch, A. W., Farooq, A., Shan, W., Zeng, L., Colman, D. R., and Zhou, M. M. (2004) Structure of the neural (N-) cadherin prodomain reveals a cadherin extracellular domain-like fold without adhesive characteristics. Structure 12, 793-805
64. Pullikotil, P., Benjannet, S., Mayne, J., and Seidah, N. G. (2007) The proprotein convertase SKI-1/S1P. Alternate translation and subcellular localization. J. Biol. Chem. 282, 27402-27413
65. Seidah, N. G., and Prat, A. (2007) The proprotein convertases are potential targets in the treatment of dyslipidemia. J. Mol. Med. 85, 685-696
66. Lenz, O., ter Meulen, J., Klenk, H. D., Seidah, N. G., and Garten, W. (2001) The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc. Natl. Acad. Sci. U.S.A. 98, 12701-12705
67. Marschner, K., Kollmann, K., Schweizer, M., Braulke, T., and Pohl, S. (2011) A key enzyme in the biogenesis of lysosomes is a protease that regulates cholesterol metabolism. Science 333, 87-90
68. Yang, J., Goldstein, J. L., Hammer, R. E., Moon, Y. A., Brown, M. S., and Horton, J. D. (2001) Decreased lipid synthesis in livers of mice with disrupted site-1 protease gene. Proc. Natl. Acad. Sci. U.S.A. 98, 13607-13612
69. Rutschmann, S., Crozat, K., Li, X., Du, X., Hanselman, J. C., Shigeoka, A. A., Brandl, K., Popkin, D. L., McKay, D. B., Xia, Y., Moresco, E. M., and Beutler, B. (2012) Hypopigmentation and maternal-zygotic embryonic lethality caused by a hypomorphic mbtps1 mutation in mice. G3 2, 499-504
70. Schjoldager, K. T., Vester-Christensen, M. B., Bennett, E. P., Levery, S. B., Schwientek, T., Yin, W., Blixt, O., and Clausen, H. (2010) O-Glycosylation modulates proprotein convertase activation of angiopoietin-like protein 3. Possible role of polypeptide GalNAc-transferase-2 in regulation of concentrations of plasma lipids. J. Biol. Chem. 285, 36293-36303
71. Patra, D., Xing, X., Davies, S., Bryan, J., Franz, C., Hunziker, E. B., and Sandell, L. J. (2007) Site-1 protease is essential for endochondral bone formation in mice. J. Cell Biol. 179, 687-700
72. Pasquato, A., Rochat, C., Burri, D. J., Pasqual, G., de la Torre, J. C., and Kunz, S. (2012) Evaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-429242. Virology 423, 14-22
73. Blanchet, M., Seidah, N. G., and Labonté, P. (2012) SKI-1/S1P inhibition: a promising surrogate to statins to block hepatitis C virus replication. Antiviral Res. 95, 159-166
74. Maxwell, K. N., and Breslow, J. L. (2004) Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. U.S.A. 101, 7100-7105
75. Benjannet, S., Rhainds, D., Essalmani, R., Mayne, J., Wickham, L., Jin, W., Asselin, M.-C., Hamelin, J., Varret, M., Allard, D., Trillard, M., Abifadel, M., Tebon, A., Attie, A. D., Rader, D. J., Boileau, C., Brissette, L., Chrétien, M., Prat, A., and Seidah, N. G. (2004) NARC-1/PCSK9 and its natural mutants. Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279, 48865-48875
76. Seidah, N. G. (2013) Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. Curr. Pharm. Des 19, 3161-3172
77. Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., and Hobbs, H. H. (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37, 161-165
78. Denis, M., Marcinkiewicz, J., Zaid, A., Gauthier, D., Poirier, S., Lazure, C., Seidah N. G., and Prat, A. (2012) Gene inactivation of PCSK9 reduces atherosclerosis in mice. Circulation 125, 894-901
79. Cunningham, D., Danley, D. E., Geoghegan, K. F., Griffor, M. C., Hawkins, J. L., Subashi, T. A., Varghese, A. H., Ammirati, M. J., Culp, J. S., Hoth, L. R., Mansour, M. N., McGrath, K. M., Seddon, A. P., Shenolikar, S., Stutzman-Engwall, K. J., Warren, L. C., Xia, D., and Qiu, X. (2007) Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 14, 413-419
80. Chen, X. W., Wang, H., Bajaj, K., Zhang, P., Meng, Z. X., Ma, D., Bai, Y., Liu, H. H., Adams, E., Baines, A., Yu, G., Sartor, M. A., Zhang, B., Yi, Z., Lin, J., Young, S. G., Schekman, R., and Ginsburg, D. (2013) SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion. eLIFE 2, e00444
81. Poirier, S., Mayer, G., Poupon, V., McPherson, P. S., Desjardins, R., Ly, K., Asselin, M.-C., Day, R., Duclos, F. J., Witmer, M., Parker, R., Prat, A., and Seidah, N. G. (2009) Dissection of the endogenous cellular pathways of PCSK9-induced LDLR degradation. Evidence for an intracellular route. J. Biol. Chem. 284, 28856-28864
82. Nassoury, N., Blasiole, D. A., Tebon Oler, A., Benjannet, S., Hamelin, J., Poupon, V., McPherson, P. S., Attie, A. D., Prat, A., and Seidah, N. G. (2007) The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 8, 718-732
83. Saavedra, Y. G., Day, R., and Seidah, N. G. (2012) The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 is needed for the extracellular low density lipoprotein receptor (LDLR) degradation pathway. J. Biol. Chem. 287, 43492-43501
84. Benjannet, S., Saavedra, Y. G., Hamelin, J., Asselin, M.-C., Essalmani, R., Pasquato, A., Lemaire, P., Duke, G., Miao, B., Duclos, F., Parker, R., Mayer, G., and Seidah, N. G. (2010) Effects of the prosegment and pH on the activity of PCSK9. Evidence for additional processing events. J. Biol. Chem. 285, 40965-40978
85. Kosenko, T., Golder, M., Leblond, G., Weng, W., and Lagace, T. A. (2013) Low density lipoprotein binds to proprotein convertase subtilisin/ kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. J. Biol. Chem. 288, 8279-8288
86. Strøm, T. B., Holla, ø. L., Tveten, K., Cameron, J., Berge, K. E., and Leren, T. P. (2010) Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain. Mol. Genet. Metab. 101, 76-80
87. Zhang, D. W., Garuti, R., Tang, W. J., Cohen, J. C., and Hobbs, H. H. (2008) Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc. Natl. Acad. Sci. U.S.A. 105, 13045-13050
88. DeVay, R. M., Shelton, D. L., and Liang, H. (2013) Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2). J. Biol. Chem. 288, 10805-10818
89. Benjannet, S., Rhainds, D., Hamelin, J., Nassoury, N., and Seidah, N. G. (2006) The proprotein convertase PCSK9 is inactivated by furin and/or PC5/6A. Functional consequences of natural mutations and post-translational modifications. J. Biol. Chem. 281, 30561-30572
90. Lipari, M. T., Li, W., Moran, P., Kong-Beltran, M., Sai, T., Lai, J., Lin, S. J., Kolumam, G., Zavala-Solorio, J., Izrael-Tomasevic, A., Arnott, D., Wang, J., Peterson, A. S., and Kirchhofer, D. (2012) Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels. J. Biol. Chem. 287, 43482-43491
91. Roubtsova, A., Munkonda, M. N., Awan, Z., Marcinkiewicz, J., Chamberland, A., Lazure, C., Cianflone, K., Seidah, N. G., and Prat, A. (2011) Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler. Thromb. Vasc. Biol. 31, 785-791
92. Poirier, S., Mayer, G., Benjannet, S., Bergeron, E., Marcinkiewicz, J., Nassoury, N., Mayer, H., Nimpf, J., Prat, A., and Seidah, N. G. (2008) The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J. Biol. Chem. 283, 2363-2372
93. Canuel, M., Sun, X., Asselin, M.-C., Paramithiotis, E., Prat, A., and Seidah N. G. (2013) Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS ONE 8, e64145
94. Mbikay, M., Sirois, F., Mayne, J., Wang, G. S., Chen, A., Dewpura, T., Prat, A., Seidah, N. G., Chretien, M., and Scott, F. W. (2010) PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett. 584, 701-706
95. Sun, X., Essalmani, R., Day, R., Khatib, A. M., Seidah, N. G., and Prat, A. (2012) Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver. Neoplasia 14, 1122-1131
96. Parker, R. A., Garcia, R. A., Ryan, C. S., Liu, X., Shipkova, P., Livanov, V., Patel, P., and Ho, S. P. (2013) Bile acid and sterol metabolism with combined HMGCoA reductase and PCSK9 suppression. J. Lipid Res. 10.1194/jlr.M038331
97. Jänis, M. T., Tarasov, K., Ta, H. X., Suoniemi, M., Ekroos, K., Hurme, R., Lehtimäki, T., Päivä, H., Kleber, M. E., März, W., Prat, A., Seidah, N. G., and Laaksonen, R. (2013) Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/ kexin type 9 (PCSK9) deficiency. Atherosclerosis 228, 380-385
98. Le May, C., Berger, J. M., Lespine, A., Pillot, B., Prieur, X., Letessier, E., Hussain, M. M., Collet, X., Cariou, B., and Costet, P. (2013) Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arterioscler. Thromb. Vasc. Biol. 33, 1484-1493
99. Mayne, J., Dewpura, T., Raymond, A., Bernier, L., Cousins, M., Ooi, T. C., Davignon, J., Seidah, N. G., Mbikay, M., and Chrétien, M. (2011) Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clin. Chem. 57, 1415-1423
100. Benjannet, S., Hamelin, J., Chrétien, M., and Seidah, N. G. (2012) Lossand gain-of-function PCSK9 variants. Cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation. J. Biol. Chem. 287, 33745-33755